Sulfonylurea drug pretreatment and functional outcome in diabetic patients with acute intracerebral hemorrhage [accepted manuscript] by Chang, Jason J. et al.
Accepted Manuscript
Sulfonylurea drug pretreatment and functional outcome in
diabetic patients with acute intracerebral hemorrhage
Jason J. Chang, Yasser Khorchid, Ali Kerro, Lucia Goodwin
Burgess, Nitin Goyal, Anne W. Alexandrov, Andrei V.
Alexandrov, Georgios Tsivgoulis
PII: S0022-510X(17)33753-X
DOI: doi: 10.1016/j.jns.2017.08.3252
Reference: JNS 15530
To appear in: Journal of the Neurological Sciences
Received date: 28 June 2017
Revised date: 24 August 2017
Accepted date: 26 August 2017
Please cite this article as: Jason J. Chang, Yasser Khorchid, Ali Kerro, Lucia Goodwin
Burgess, Nitin Goyal, Anne W. Alexandrov, Andrei V. Alexandrov, Georgios Tsivgoulis
, Sulfonylurea drug pretreatment and functional outcome in diabetic patients with acute
intracerebral hemorrhage. The address for the corresponding author was captured as
affiliation for all authors. Please check if appropriate. Jns(2017), doi: 10.1016/
j.jns.2017.08.3252
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IPT
Sulfonylurea Drug Pretreatment and Functional Outcome in Diabetic Patients with Acute 
Intracerebral Hemorrhage 
 
 
 
Jason J. Chang, MD1, Yasser Khorchid, MD2, Ali Kerro, MD2, Lucia Goodwin Burgess, BA3, 
Nitin Goyal, MD2, Anne W. Alexandrov, PhD2,4, Andrei V. Alexandrov, MD2, Georgios 
Tsivgoulis, MD, PhD2,5 
 
1Department of Critical Care, MedStar Washington Hospital Center. Washington, DC, USA. 
2Department of Neurology, University of Tennessee Health Science Center. Memphis, TN, USA 
3University of Tennessee Health Science Center College of Medicine. Memphis, TN, USA 
4Australian Catholic University. Sidney, Australia 
5Second Department of Neurology, “Attikon University Hospital”, School of Medicine, 
University of Athens. Athens, Greece 
 
 
Corresponding author: 
Jason J. Chang, MD 
Department of Critical Care 
MedStar Washington Hospital Medical Center 
110 Irving St, NW, Rm 4B42 
Washington, DC 20010. USA 
Phone: 202-877-7259, Fax: 202-877-7258 
ORCID 0000-0002-0825-3008 
jjwchang@hotmail.com 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Full Title: Sulfonylurea Drug Pretreatment and Functional Outcome in Diabetic Patients with 
Acute Intracerebral Hemorrhage  
 
Running Title: Sulfonylurea pretreatment in ICH 
 
Type: Original Investigation 
 
Abstract word count: 250 
Characters in title/ running title: 111 / 32 
Text word count: 2973 
Number of figures: 0 
Number of color figures: 0 
Number of tables: 5 
Number of supplemental figures: 1 
Number of supplemental tables: 1 
References: 29 
 
Key Words: sulfonylurea, glyburide, intracerebral hemorrhage, outcome, edema, diabetes 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Abstract 
Purpose: Intracerebral hemorrhage (ICH) is associated with poor clinical outcome and high 
mortality. Sulfonylurea (SFU) use may be a viable therapy for inhibiting sulfonylurea receptor-1 
and NCCa-ATP channels and reducing perihematomal edema and blood-brain barrier disruption. 
We sought to evaluate the effects of prehospital SFU use with outcomes in diabetic patients with 
acute ICH. 
Methods: We retrospectively analyzed a cohort of diabetic patients presenting with acute ICH at 
a tertiary care center. Study inclusion criteria included spontaneous ICH etiology and age >18 
years. Baseline clinical severity was documented using ICH-score. Hematoma volumes (HV) on 
admission were calculated using ABC/2 formula. Unfavorable functional outcome was 
documented as discharge modified Rankin Scale scores 2-6. 
Results: 230 diabetic patients with acute ICH fulfilled inclusion criteria (mean age 64±13 years, 
men 53%). SFU pretreatment was documented in 16% of the study population. Patients with 
SFU pretreatment had significantly (p<0.05) lower median ICH-scores (0, IQR:0-2) and median 
admission HV (4cm3, IQR:1-12) compared to controls [ICH-score: 1 (IQR:0-3); HV: 9cm3 
(IQR:3-20)]. SFU pretreatment was independently (p=0.033) and negatively associated with the 
cubed root of admission HV (linear regression coefficient: -0.208; 95%CI:-0.398−-0.017) in 
multiple linear regression analyses adjusting for potential confounders. Pretreatment with SFU 
was also independently (p=0.033) associated with lower likelihood of unfavorable functional 
outcome (OR=0.19; 95%CI:0.04–0.88) in multivariable logistic regression models adjusting for 
potential confounders. 
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Conclusion: SFU pretreatment may be an independent predictor for improved functional 
outcome in diabetic patients with acute ICH. This association requires independent confirmation 
in a large prospective cohort study. 
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Manuscript 
Introduction 
Intracerebral hemorrhage (ICH) accounts for 10% of 795,000 yearly new strokes [1] and 
is associated with poor clinical outcome and unimproved mortality rates [2]. ICH consists of a 
primary phase marked by hematoma volume (HV) expansion and a slower, subacute secondary 
phase marked by perihematomal edema. Major ICH trials of the past decade have largely 
targeted HV (STICH II [3], FAST [4], INTERACT 2 [5], and ATACH II [6]), but have failed to 
improve clinical outcomes in randomized-controlled settings. Greater focus on secondary 
mechanisms of injury and attenuation of subacute perihematomal edema [7] may play a role in 
improving clinical outcome after ICH.  
One potential pathophysiological mechanism for cerebral edema lies with sulfonylurea 
receptor 1 (SUR1). SUR1 is transcriptionally upregulated in focal cerebral ischemia, which 
triggers upregulation of NCCa-ATP channels and allows for passive diffusion of Na
+ and vasogenic 
edema formation [8]. NCCa-ATP channel inhibition by sulfonylureas (SFU) may lead to decreased 
cerebral edema and hemorrhagic transformation, which may consequently improve functional 
outcomes. These findings were suggested in the GAMES-pilot trial, which showed a trend 
toward lower mortality and improved functional outcome in patients with malignant ischemic 
stroke who were treated with intravenous glyburide [9]. Although the GAMES phase 2 trial 
failed to show improved clinical outcome, thirty-day mortality was significantly reduced, and 
improvement in cerebral edema was suggested by the significant reduction in subacute midline 
shift present in the glyburide group [10]. 
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As the subacute progression of perihematomal edema may play a role in ICH, we sought 
to evaluate the effects of prehospital SFU use in clinical outcomes of patients with acute ICH and 
diabetes.  
 
Methods  
Patient Selection and Study Protocol 
Institutional review board approval was obtained for the conduct of a prospective cohort 
study evaluating functional outcomes in adult non-traumatic ICH patients at a tertiary-level 
hospital. All data was prospectively collected for acute (< 24 hours) ICH and retrospectively 
reviewed for accuracy by blinded neurologists (YK and AK). Consecutive patients with ICH 
meeting inclusion criteria were initially identified by ICD code during the period January 2011 to 
December 2015. 
Study inclusion criteria included history of diabetes mellitus (DM) as documented by past 
medical history or hemoglobin A1c levels > 7.0 [11], spontaneous ICH etiology, and age > 18 
years old. Exclusion criteria included structural etiology for ICH (attributable to trauma or 
underlying vascular lesions such as cavernous malformation, arteriovenous malformation, or 
arterial-venous fistula), coagulopathy (INR > 1.7), and thrombocytopenia (platelets < 
50,000/mm3). As per hospital protocol, all oral diabetic medications (including SFUs) were 
stopped on admission and replaced with sliding scale insulin and long-acting insulin. 
Pretreatment SFUs included glipizide, glyburide, and glimepiride. 
Demographics and vascular risk factors were documented at hospital admission as 
previously described [12]. Baseline clinical severity was documented using ICH-score [13] and 
National Institutes of Health Stroke Scale (NIHSS) score [12]. Clinical outcome endpoints 
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included modified Rankin Scale score (mRS) at discharge, hospital length of stay, disposition, 
and in-hospital mortality. ICH-score, NIHSS scores, and mRS-scores were documented by 
certified vascular neurologists (YK and AK) blinded to SFU pretreatment. Admission HV was 
calculated using the ABC/2 formula [14]. Significant hematoma expansion was defined as a 
proportional increase of greater than 33% or an absolute increase greater than 12.5 mL from the 
initial ICH volume [15,16]. HV at admission, follow-up neuroimaging, and hematoma expansion 
were evaluated by neuroradiologists blinded to SFU pretreatment. The following in-hospital 
complications were prospectively recorded: decompressive hemicraniectomy, vasopressor use, 
respiratory failure, and external ventricular drain placement.  
Statistical analysis 
Initial demographic differences, neuroimaging features, in-hospital complications, and 
outcomes between the pretreated SFU and non-pretreated SFU groups were evaluated with 
independent samples t-test, χ2 test, Mann-Whitney U test, and Cochran-Mantel-Haenszel shift 
test as appropriate. Kolmogorov-Smirnov goodness-of-fit test was used to evaluate for normal 
distribution of continuous variables.  
HV was not found to have a normal distribution (p< 0.001 by Kolmogorov-Smirnov test) 
and was cube root transformed for each patient to satisfy Kolmogorov-Smirnov goodness-of-fit 
test (p= 0.200) regarding normality [17]. The cubed root of HV (CRHV) was utilized as the 
dependent variable in simple and multiple linear regression models evaluating independent 
associations between baseline characteristics and admission HV. A p value of < 0.1 was selected 
as a cut-off in simple linear regression analyses for inclusion of candidate variables in the 
multiple linear regression model. Predictor variables that were significant at p< 0.05 were 
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retained in the multiple linear regression model. Associations are presented as unstandardized 
linear regression coefficients with corresponding 95% CIs.  
 Univariable and backward selection multivariable logistic regression analyses were used 
to determine independent predictors of dichotomized baseline ICH-score and functional outcome 
at discharge. ICH-score was dichotomized to “mild” (ICH-score 0-1) or “severe” (ICH-score 2-
6) based on the median ICH score of the study population (1 point). Functional outcome at 
discharge was dichotomized into “favorable” [modified Rankin score (mRS) of 0-2] and 
“unfavorable” (mRS score of 3-6) as previously described [12]. A p value of < 0.1 was selected 
as a cut-off in univariable logistic regression analyses for inclusion of candidate variables in the 
multivariable logistic regression models. Predictor variables that were significant at p< 0.05 were 
retained in the multivariable model. Associations are presented as OR with corresponding 95% 
CIs. The Statistical Package for Social Science (version 17.0 for Windows; SPSS Inc., Chicago, 
IL) was used for statistical analyses. 
 
Results  
A total of 790 patients were identified by ICD code and confirmed by chart review as 
ICH patients in this time span. We excluded 118 ICH patients because of coagulopathy, 
thrombocytopenia, or underlying structural lesions. The remaining 672 patients had spontaneous 
ICH, of which 230 patients had spontaneous ICH, a past history of DM, and fulfilled the 
remaining inclusion criteria (supplemental Figure I). Study population mean age was 64±13 
years (53% men). We identified 37 patients with SFU pretreatment (mean age 67±10 years, 41% 
men) vs. 193 patients without SFU pretreatment (mean age 63±13 years, 55% men). Baseline 
characteristics are shown in Table 1. The two groups did not differ in baseline characteristics 
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including demographics, vascular risk factors, pre-hospital use of antiplatelets, anticoagulants or 
statins, admission blood pressure values, serum creatinine, and glucose levels. The two groups 
had similar coagulation profiles in terms of baseline platelet number and international 
normalized ratio. 
Table 2 summarizes clinical and radiological outcomes as well as in-hospital 
complications between the two groups. Patients with SFU pretreatment had significantly lower 
median ICH-score [0 points (interquartile range (IQR): 0-2) vs. 1 point (IQR:0-3); p= 0.021] and 
lower median HV [4cm3 (IQR:1-12) vs. 9cm3 (IQR: 3-20) p=0.026]. Mild ICH severity (ICH 
score of 0-1) was documented more frequently in patients pretreated with SFU (75% vs. 54%; p= 
0.019). The rates of hematoma expansion did not differ (p= 0.184) in the two groups. In-hospital 
complications favored the group with SFU pretreatment with lower rates of external ventricular 
drain placement (5% vs. 20%; p= 0.034) and respiratory failure (19% vs. 40%; p= 0.015). The 
median duration of hospitalization was significantly shorter in the pretreated SFU group [median 
duration 5 (IQR:3-7) days vs. 7 (IQR:4-15) days; p= 0.012]. Functional improvement at hospital 
discharge was greater in the group of patients pretreated with SFU [median mRS-score 3 (IQR:1-
5) vs. 4 (IQR:2-5); p= 0.034 by Cochran Mantel Haenszel shift test]. Unfavorable functional 
outcome at discharge was less prevalent in the SFU group (54% vs. 72%; p= 0.028). The rates of 
in-hospital mortality were similar (p= 0.771) in the two groups.  
Table 3 depicts associations between baseline characteristics and CRHV in simple and 
multiple linear regression models. CRHV was associated (p< 0.1) with the following variables in 
simple linear regression analyses: NIHSS-score at admission (p< 0.001), prior stroke (p= 0.025), 
hyperlipidemia (p= 0.057), prehospital antiplatelet use (p= 0.083), prehospital SFU use (p= 
0.044), and platelets at admission (p= 0.076). In multiple linear regression analysis, SFU 
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pretreatment (p= 0.033) was independently and negatively associated with CRHV (linear 
regression coefficient -0.208, 95%CI: -0.398− -0.017). Higher baseline NIHSS-scores and prior 
antiplatelet use remained independently (p< 0.05) associated with larger CRHV in multiple 
linear regression models. 
Table 4 depicts associations between baseline characteristics and mild ICH-score (0-1) in 
univariable and multivariable logistic regression models. The following variables were 
associated (p< 0.1) with mild ICH-score in univariable analyses: age (p= 0.008), body mass 
index (BMI; p= 0.042), NIHSS-score at admission (p< 0.001), hypertension (p= 0.019), prior 
stroke (p= 0.042), hyperlipidemia (p= 0.093), prehospital SFU use (p= 0.022), admission glucose 
(p= 0.028), systolic blood pressure at admission (p= 0.004), and diastolic blood pressure at 
admission (p= 0.036). Admission NIHSS-score, age and prehospital SFU use remained 
independently (p< 0.05) associated with ICH-score in the final multivariable logistic regression 
model. More specifically, SFU pretreatment was independently related to higher odds of mild 
ICH-score (OR: 11.91, 95%CI 2.74–51.80; p=0.001), while increasing age and increasing 
admission NIHSS-scores were associated with a lower likelihood of mild ICH-score at baseline.   
Table 5 depicts associations between baseline characteristics and unfavorable functional 
outcome (mRS-score of 3-6) at discharge in univariable and multivariable logistic regression 
models. The following variables were associated (p< 0.1) with unfavorable functional outcome 
in univariable analyses: age (p= 0.091), BMI (p= 0.063), NIHSS-score at admission (p< 0.001), 
subcortical location (p= 0.056), HV at admission (p< 0.001), intraventricular hemorrhage (p< 
0.001), history of hypertension (p= 0.091), prehospital antiplatelet use (p= 0.037), prehospital 
SFU use (p= 0.031), admission systolic blood pressure (p= 0.006), and admission diastolic blood 
pressure (p= 0.028). Admission NIHSS-score, age, admission HV and prehospital SFU use 
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remained independently (p< 0.05) associated with unfavorable functional outcome in the final 
multivariable logistic regression model. SFU pretreatment was independently related to lower 
odds of unfavorable functional outcome (OR: 0.19; 95%CI: 0.04-0.88; p= 0.033), while 
increasing age and increasing admission NIHSS-scores were associated with a higher likelihood 
of unfavorable functional outcome at discharge.  
We also repeated our multivariable logistic regression analyses using forward selection 
procedure. The association between SFU pretreatment and lower likelihood of unfavorable 
functional outcome was almost identical (OR: 0.12; 95%CI: 0.020-0.64; p= 0.013). Additionally, 
when we used a different cut-off for discharge mRS-score (0-1 vs. 2-6), SFU pretreatment 
remained independently associated with a lower likelihood of unfavorable functional outcome 
(mRS-score 2-6) at discharge in multivariable logistic regression models adjusting for potential 
confounders (OR: 0.12; 95%CI: 0.023-0.059; p= 0.010; Supplemental Table I).  
 
Discussion 
Our study is the first to report a potential beneficial effect of SFU pretreatment in the 
outcomes of diabetic patients with acute ICH. We documented that patients pretreated with SFU 
had lower ICH-scores and smaller HV at hospital admission compared to patients without SFU 
pretreatment. Moreover, prehospital SFU use was associated with lower likelihood of 
unfavorable functional outcome at hospital discharge, which remained consistent regardless of 
mRS dichotomization of "unfavorable outcome". The former three associations persisted after 
multivariable adjustment for potential confounders including demographics, vascular risk 
factors, coagulation parameters, admission blood pressure values, serum blood glucose, and 
creatinine levels. 
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SUR1 is transcriptionally upregulated in focal cerebral ischemia [18] via the transcription 
factor Sp1 [8]. The activation of SUR1-NCCa-ATP channels leads to an initial cytotoxic edema, 
which is then followed by passive influx of chloride ions and water, resulting in a subsequent 
vasogenic “malignant” cerebral edema [8,19] and poor clinical outcomes. In addition, SFUs have 
been suggested as potential matrix metalloproteinases-9 (MMP-9) inhibitors [10,20,21], which 
leads to decreased blood-brain barrier disruption and hemorrhagic transformation [22,23]. 
Finally, rat models for ischemic stroke have suggested that SFU inhibition of SUR1-NCCa-ATP 
channels may also reduce apoptosis [24]. 
SFUs potentially inhibit progression of vasogenic edema by directly inhibiting SUR1-
NCCa-ATP channels. Animal models have demonstrated SFUs improving clinical outcome after 
ischemic stroke [9,25], subarachnoid hemorrhage [26], and brain metastases [27]. The role of 
SFUs in decreasing vasogenic edema and improving cognitive deficits has also been 
demonstrated in rat models of ICH [28]. 
However, to date, no study has evaluated the association of SFU pretreatment with 
imaging and clinical outcomes in humans with ICH. Our findings indicate that the potential 
beneficial effect of SFU pretreatment in early functional outcomes of patients with acute ICH is 
not be solely attributed to attenuation of admission HV, since in our multivariable analyses SFU 
pre-hospital use was related to greater functional improvement at discharge even after adjustment 
for baseline HV, stroke severity, and ICH location. Notably, this association was independent of 
the selected mRS cut-offs (0-2 vs. 3-6 or 0-1 vs. 2-6) and persisted across the whole distribution 
mRS-scores (Cochran-Mantel-Haenszel test). Further research is required to elucidate the 
underlying mechanisms that may account for the beneficial impact of SFU pretreatment on 
functional outcomes in patients with spontaneous ICH. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Interestingly, one shortcoming of all major ICH trials of the past decade may be their sole 
focus on stopping primary phase HV expansion through surgical decompression (STICH II [3]), 
hemostasis (FAST [4]), or intensive blood pressure control (INTERACT 2 [5] and ATACH II 
[6]). The failure of these trials may introduce the necessity of providing therapies to reduce 
secondary mechanisms of injury: blood-brain barrier destruction, vasogenic edema, and 
pathological MMP-9 activation. The mechanisms of action of SFUs are inherently designed to 
target this secondary phase of ICH. Better elucidation of these mechanisms and therapies may 
prove a more promising target for improving clinical outcome in the future. 
Several limitations need to be acknowledged when interpreting the findings of the present 
study. First, the modest sample size, retrospective study design, and non-randomized patient 
selection was a major methodological shortcoming of this research. This may have led to smaller 
HVs in the SFU pretreated group, which may have affected final outcomes. However, it should 
be noted that data was collected prospectively, while neurologists and neuroradiologists 
evaluating clinical and neuroimaging outcomes were blinded to SFU pretreatment.  
Second, as per policy at our hospital, all oral diabetes medications were discontinued 
upon hospital admission and replaced with insulin during critical care management. This may 
question the efficacy of SFUs in our study. However, despite being discontinued, the half-lives 
of glyburide (7-10 hours), glipizide (2-4 hours), and glimepiride (5-8 hours) allow for the 
possibility that the drugs may have still been present as short as eight hours and as long as forty 
hours after hospitalization. Rodent models, suggesting that SUR1 is upregulated approximately 
2-3 hours in the core and 8-16 hours in the penumbra region after ischemic injury [8] allows for 
the possibility that the effects of the SFUs may still have been present despite being 
discontinued. Additionally, rat models with SFU injection twenty-four hours after induction of 
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ischemia have demonstrated long-term neuroprotection associated with neuroblast migration 
toward the ischemic core [29].  
Third, perihematomal edema volumes were not measured on admission nor were follow-
up images consistently obtained. Therefore, although pretreatment with SFUs was shown to be 
an independent predictor of good functional outcome, with other multivariable regression 
analysis suggesting this was not due to admission HV or admission clinical condition, the 
proposed mechanism of blood-brain barrier preservation and decreased vasogenic edema could 
not be definitively confirmed.  
Fourth, HV for our ICHs was estimated using ABC/2 formula. Slight variations may have 
existed, however, Kothari et al. demonstrated extremely high correlations (R2 = 0.96) between 
planimetric measurements and ABC/2 estimation of HV [14].  
And finally, functional outcomes were assessed at discharge and not at three-months and 
this may have confounded the reported associations. However, the improvement in functional 
outcome in the SFU pretreatment group was robust across several categories: significant 
improvement both in shift of mRS-score and in different dichotomized mRS-scores (when 
unfavorable outcome was delineated as mRS 3-6 or mRS 2-6), shorter length of hospitalization, 
and a strong trend when evaluating disposition.  
 
Conclusion 
In conclusion, this pilot, single-center study provides preliminary evidence indicating that 
SFU pretreatment may be an independent predictor for smaller initial HV, milder admission ICH 
severity, and improved functional outcome at discharge in diabetic patients with acute ICH. 
These intriguing observations require independent confirmation by larger, multi-center 
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prospective studies with careful design taking into account specific neuroimaging 
(perihematomal edema volume) and biochemical (MMP-9 levels) parameters that may provide 
additional insight regarding the potential underlying mechanisms and establish a causal 
association between SFU pretreatment and improved clinical outcomes in diabetic patients with 
acute ICH. 
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Table 1: Baseline characteristics in intracerebral hemorrhage patients with history of diabetes stratified by 
sulfonylurea pretreatment 
 
Baseline characteristic SFU pretreatment 
(n=37) 
No SFU pretreatment 
(n=193) 
p 
Mean age, years (SD) 67 (10) 63 (13) 0.079 
Male gender, % 41% 55% 0.109 
African American race, % 73% 73% 0.957 
Mean BMI, kg/m
2
 (SD) 33.10 (6.22) 31.02 (7.72) 0.124 
Hypertension, % 97% 92% 0.267 
Coronary Artery Disease, % 22% 18% 0.564 
Congestive Heart Failure, % 11% 10% 0.999* 
Prior Stroke, % 22% 22% 0.985 
Chronic Kidney Disease, % 19% 20% 0.858 
Alcohol use, % 18% 20% 0.864 
Smoker, % 24% 29% 0.591 
Hyperlipidemia, % 49% 40% 0.314 
Prehospital Antiplatelet use, % 47% 38% 0.274 
Prehospital Anticoagulation use, % 8% 2% 0.090* 
Prehospital Statin, % 38% 32% 0.509 
Median serum glucose, mg/dl (interquartile 
range) 
182 (148-269) 171 (133-243) 0.417 
Median INR (interquartile range) 1.10 (1.00-1.10) 1.00 (1.00-1.10) 0.802 
Mean number of platelets, 10
3
/μL(SD) 229 (66) 229 (81) 0.965 
Median serum creatinine, mg/dl (interquartile 
range) 
1.10 (0.80-1.30) 1.20 (0.90-1.80) 0.128 
Mean admission systolic blood pressure, 
mmHg (SD) 
177 (40) 187 (37) 0.138 
Mean admission diastolic blood pressure, 
mmHg (SD) 
94 (21) 103 (26) 0.057 
 
SD: standard deviation; SFU: sulfonylurea; BMI: body mass index; INR: international normalized ratio  
* p value was calculated by Fisher’s exact test  
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Table 2. Baseline stroke severity, neuroimaging parameters, in-hospital complications and outcomes in intracerebral 
hemorrhage patients with history of diabetes stratified by sulfonylurea pretreatment  
 
Variables SFU pretreatment 
(n=37) 
No SFU 
pretreatment 
(n=193) 
p 
Stroke Severity    
   Median NIHSS-score, points (IQR) 6 (2-17) 10 (3-18) 0.225 
   Median ICH score, points (IQR) 0 (0-2) 1 (0-3) 0.021 
   Mild ICH score (0-1), % 75% 54% 0.019 
Neuroimaging Findings    
   Subcortical location, % 57% 63% 0.449 
   Intraventricular Hemorrhage, % 35% 47% 0.170 
   Median ICH hematoma volume, cm
3
 (IQR) 4 (1-12) 9 (3-20) 0.026 
   Hematoma Expansion, % 26% 14% 0.184 
Complications    
   Hemicraniectomy, % 0% 8% 0.138* 
   Vasopressor, % 0% 2% 0.999* 
   Respiratory Failure, % 19% 40% 0.015 
   External Ventricular Drain, % 5% 20% 0.034* 
Outcomes     
   Length of Hospitalization (days)  5 (3-7) 7 (4-15) 0.012 
   Median mRS-score at discharge (IQR) 3 (1-5) 4 (2-5) 0.034
 a
 
   Unfavorable functional Outcome
 b
, %  54% 72% 0.028 
   Poor Disposition
 c
, % 30% 47% 0.058 
   In-hospital death, % 22% 24% 0.771 
 
NIHSS: National Institute of Health Stroke Scale; IQR: interquartile range;  
 mRS: modified Rankin Scale  
* p value was calculated by Fisher’s exact test  
a
 p-value was calculated by Cochran-Mantel-Haenszel shift test 
b
 unfavorable functional outcome: mRS score 3-6 at hospital discharge 
c
 poor disposition: disposition to skilled nursing facility, hospice, or death  
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Table 3: Simple and multiple linear regression analyses depicting associations between baseline characteristics and 
cubed root of admission hematoma volume 
 
 Simple Linear Regression 
Analysis 
Multiple Linear Regression 
Analysis 
Variable Linear Regression 
Coefficient (95% CI) 
p* Linear Regression 
Coefficient (95% CI) 
p 
Age +0.003 (-0.003−0.009) 0.357   
Gender -0.087 (-0.246−0.071) 0.279   
African American Race -0.084 (-0.265−0.096) 0.359   
BMI -0.004 (-0.014−0.007) 0.484   
NIHSS-score at admission +0.026 (0.020−0.032) < 0.001 +0.025 (0.019−0.031) < 0.001 
Subcortical location -0.094 (-0.260−0.073) 0.269   
Hypertension -0.016 (-0.343−0.312) 0.925   
Coronary artery disease +0.143 (-0.061−0.347) 0.169   
Congestive heart failure +0.071 (-0.184−0.327) 0.583   
Prior stroke -0.220 (-0.412−-0.027) 0.025 -0.205 (-0.381−-0.030) 0.022 
Chronic kidney disease +0.071 (-0.126−0.269) 0.477   
Alcohol use +0.061 (-0.144−0.266) 0.559   
Smoker -0.078 (-0.260−0.105) 0.403   
Hyperlipidemia -0.156 (-0.317−0.004) 0.057 -0.099 (-0.249−0.050) 0.193 
Prehospital Antiplatelet use +0.147 (-0.019−0.314) 0.083 +0.237 (0.088−0.385) 0.002 
Prehospital Anticoagulation use  -0.157 (-0.650−0.335) 0.529   
Prehospital Statin use -0.128 (-0.303−0.047) 0.151   
Prehospital Sulfonylurea use -0.223 (-0.439−-0.006) 0.044 -0.208 (-0.398−-0.017) 0.033 
INR at admission +0.079 (-0.333−0.492) 0.706   
Serum Glucose at admission -0.000 (-0.001−0.001) 0.550   
Platelets at admission  
(per 1.000/μL increase) 
-0.001 (-0.002−0.000) 0.076 +0.000 (-0.001−0.001) 0.449 
Serum Creatinine at admission -0.005 (-0.053−0.043) 0.845   
Systolic blood pressure at 
admission 
+0.000 (-0.002−0.002) 0.708   
Diastolic blood pressure at 
admission 
+0.001 (-0.002−0.004) 0.481   
 
NIHSS: National Institutes of Health Stroke Scale; BMI = body mass index; INR = international normalized ratio  
*cutoff of p< 0.1 was used for selection of candidate variables for inclusion in multiple linear regression models  
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Table 4: Univariable and multivariable logistic regression analyses depicting the associations between baseline 
characteristics and mild ICH score (0-1) at admission. 
 
  
Univariable Logistic  Multivariable Logistic Regression 
Analysis Regression Analysis 
Variable 
Odds Ratio 
(95% CI) 
p* 
Odds Ratio 
(95% CI) 
p 
Age 0.97 (0.95-0.99) 0.008 0.91 (0.87-0.95) <0.001 
Gender 1.01 (0.59-1.71) 0.983 
  
African American Race 0.80 (0.44-1.45) 0.46 
  
BMI 1.04 (1.00-1.08) 0.042 1.04 (0.98-1.11) 0.194 
NIHSS-score at admission 0.81 (0.77-0.86) < 0.001 0.77 (0.72-0.83) < 0.001 
Subcortical location 0.85 (0.49-1.46) 0.546 
  
Hypertension 0.09 (0.01-0.67) 0.019 0.03 (0.00-1.10) 0.056 
Coronary artery disease 0.74 (0.38-1.46) 0.382 
  
Congestive heart failure 0.88 (0.36-2.14) 0.781 
  
Prior stroke 2.01 (1.03-3.95) 0.042 2.82 (0.85-9.45) 0.092 
Chronic kidney disease 1.12 (0.57-2.21) 0.75 
  
Prior Alcohol use 1.31 (0.65-2.64) 0.451 
  
Smoker 0.71 (0.39-1.29) 0.257 
  
Hyperlipidemia 1.60 (0.92-2.77) 0.093 1.31 (0.51-3.33) 0.573 
Prehospital antiplatelet use 0.95 (0.55-1.65) 0.851 
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Prehospital anticoagulation use 1.49 (0.27-8.32) 0.648 
  
Prehospital statin use 1.54 (0.86-2.77) 0.146 
  
Prehospital SFU use 2.56 (1.14-5.73) 0.022 11.91 (2.74-51.80) 0.001 
Glucose (per 10mg/dL increase) 0.97 (0.95-1.00) 0.028 0.97 (0.93-1.01) 0.181 
INR at admission 1.03 (0.42-2.50) 0.948 
  
Platelets at admission 
1.00 (0.99-1.01) 0.28 
  
(per 1.000/μL increase) 
Creatinine at admission 0.97 (0.84-1.17) 0.917 
  
Systolic blood pressure at 
admission (per 10mmHg 
increase) 
0.90 (0.84-0.97) 0.004 0.95 (0.79-1.15) 0.613 
Diastolic blood pressure at 
admission (per 10mmHg 
increase) 
0.89 (0.80-0.99) 0.036 0.97 (0.71-1.34) 0.869 
 
 
NIHSS: National Institutes of Health Stroke Scale; BMI = body mass index; INR = international  
normalized ratio 
*cutoff of p< 0.1 was used for selection of candidate variables for inclusion in multiple logistic regression models  
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Table 5: Univariable and multivariable logistic regression analyses depicting the associations between baseline 
characteristics and unfavorable functional outcome at discharge (modified Rankin Scale score of 3-6). 
 Univariable Logistic Regression 
Analysis 
Multivariable Logistic  
Regression Analysis 
Variable Odds Ratio (95% CI) p* Odds Ratio (95% CI) p 
Age 1.02 (1.00-1.04) 0.091 1.10 (1.03-1.17) 0.003 
Gender 1.23 (0.70-2.16) 0.479   
African American Race 1.31 (0.71-2.43) 0.394   
BMI 0.97 (0.93-1.00) 0.063 0.99 (0.92-1.05) 0.540 
NIHSS-score at admission 1.51 (1.33-1.72) < 0.001 1.89 (1.50-2.43) < 0.001 
Subcortical location 1.76 (0.99-3.14) 0.056 0.86 (0.28-2.67) 0.797 
ICH volume at admission 1.08 (1.04-1.12) < 0.001 0.94 (0.88-0.99) 0.028 
Intraventricular hemorrhage 5.07 (2.60-9.86) < 0.001 3.34 (0.90-12.36) 0.071 
Hematoma Expansion 1.18 (0.45-3.10) 0.730   
Hypertension 2.42 (0.87-6.73) 0.091 0.91 (0.15-5.63) 0.923 
Coronary artery disease 0.82 (0.40-1.69) 0.598   
Congestive heart failure 2.26 (0.74-6.89) 0.154   
Prior stroke 0.93 (0.47-1.82) 0.822   
Chronic kidney disease 0.98 (0.48-1.98) 0.947   
Prior Alcohol use 0.81 (0.40-1.65) 0.560   
Smoker 1.48 (0.76-2.86) 0.248   
Hyperlipidemia 0.65 (0.36-1.16) 0.141   
Prehospital antiplatelet use 0.92 (0.51-1.66) 0.792   
Prehospital anticoagulation use 0.17 (0.03-0.90) 0.037 0.001 (0.000-7.67) 0.938 
Prehospital statin use 0.99 (0.53-1.83) 0.967   
Prehospital SFU use 0.45 (0.22-0.93) 0.031 0.19 (0.04-0.88) 0.033 
Glucose (per 10mg/dL increase) 1.01 (0.98-1.03) 0.626   
INR at admission 0.64 (0.26-1.60) 0.339   
Platelets at admission 
(per 1.000/μL increase) 
1.00 (0.99-1.01) 0.650   
Creatinine at admission 1.01 (0.85-1.20) 0.943   
Systolic blood pressure at 
admission (per 10mmHg increase) 
1.12 (1.03-1.21) 0.006 1.07 (0.86-1.32) 0.561 
Diastolic blood pressure at 
admission (per 10mmHg increase) 
1.14 (1.02-1.28) 0.028 1.22 (0.83-1.79) 0.310 
ICH: intracerebral hemorrhage; NIHSS: National Institutes of Health Stroke Scale; BMI: body mass index; INR: 
international normalized ratio 
*cutoff of p< 0.1 was used for selection of candidate variables for inclusion in multiple logistic regression model.  
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Highlights for Review 
 Intracerebral hemorrhage remains associated with poor clinical outcome 
 SUR-1-NCCa-ATP channels may provide a viable therapeutic target for neuroprotection 
 Sulfonylurea pretreatment in diabetic patients with ICH may improve outcome 
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